MANNKIND ANNOUNCES IND CLEARANCE FROM U.S. FDA TO START PHASE 3 STUDY OF CLOFAZIMINE INHALATION SUSPENSION FOR NTM LUNG DISEASE
Midas Pharma obtains CEP for Clofazimine
New COVID-19 drugs such as Gilead Sciences’ remdesivir have their limitations, stressing the need for additional therapeutic options. To accelerate the drug development process, scientists have been looking to repurpose existing medicines. Now, an international team has locked onto an old leprosy drug, clofazimine, as a promising candidate.
WESTLAKE VILLAGE, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it has acquired QrumPharma, Inc., a privately held pharmaceutical company developing inhalation treatments for severe chronic and recurrent pulmonary infections, including Nontuberculous Mycobacterial (NTM) lung disease.